The event will include an overview of hyperhidrosis and atopic dermatitis and the current treatment landscapes, the market opportunity and commercial plans for glycopyrronium tosylate, and the lebrikizumab development program.
To view and listen to the webcast, please visit Dermira’s website at http://investor.dermira.com. Visitors will also be able to view and listen to an archive of the webcast found in the Investor Relations section of www.dermira.com. An archive will be available for 30 days following the event.
For registration and more information on the Analyst & Investor Day please refer to the contact information within this press release.
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s pipeline includes two late-stage product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate (formerly DRM04), for which a New Drug Application is under review by the U.S. Food and Drug Administration for the treatment of primary axillary hyperhidrosis (excessive underarm sweating beyond what is needed for normal body temperature regulation), and lebrikizumab, in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. Dermira is headquartered in Menlo Park, Calif. For more information, please visit http://www.dermira.com. Follow
In addition to filings with the Securities and Exchange Commission (
Vice President, Corporate Communications
Vice President, Investor Relations
Source: Dermira, Inc.